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Abstract
Dysregulation of mesolimbic dopamine transmission is implicated in a number of psychiatric illnesses characterised by
disruption of reward processing and goal-directed behaviour, including schizophrenia, drug addiction and impulse control
disorders associated with chronic use of dopamine agonists. Amphetamine sensitization (AS) has been proposed to model
the development of this aberrant dopamine signalling and the subsequent dysregulation of incentive motivational
processes. However, in humans the effects of AS on the dopamine-sensitive neural circuitry associated with reward
processing remains unclear. Here we describe the effects of acute amphetamine administration, following a sensitising
dosage regime, on blood oxygen level dependent (BOLD) signal in dopaminoceptive brain regions during a rewarded
gambling task performed by healthy volunteers. Using a randomised, double-blind, parallel-groups design, we found clear
evidence for sensitization to the subjective effects of the drug, while rewarded reaction times were unchanged. Repeated
amphetamine exposure was associated with reduced dorsal striatal BOLD signal during decision making, but enhanced
ventromedial caudate activity during reward anticipation. The amygdala BOLD response to reward outcomes was blunted
following repeated amphetamine exposure. Positive correlations between subjective sensitization and changes in
anticipation- and outcome-related BOLD signal were seen for the caudate nucleus and amygdala, respectively. These data
show for the first time in humans that AS changes the functional impact of acute stimulant exposure on the processing of
reward-related information within dopaminoceptive regions. Our findings accord with pathophysiological models which
implicate aberrant dopaminergic modulation of striatal and amygdala activity in psychosis and drug-related compulsive
disorders.
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Introduction
Repeated intermittent administration of psychostimulants, such
as cocaine or amphetamine, is associated with a progressive
sensitivity to the drug’s effects [1–3], termed sensitization. In
rodent models drug-induced hyperlocomotion and increased
sensitivity to stressors are commonly observed [4,5], associated
with an enhanced ability of the drug [6,7], or a stressor [8], to
release dopamine (DA) in the nucleus accumbens. Such dysreg-
ulation of mesolimbic DA signalling has been posited as a model of
dopaminergic abnormalities during the development of schizo-
phrenia [9,10], drug addiction [11], their co-morbidity [12], drug-
induced psychosis [13] and impulse control disorders seen in some
patients with Parkinson’s disease following chronic exposure to
dopamine agonists [14,15]. Support for sensitization in these
disorders comes from PET studies showing enhanced striatal DA
release in response to dopaminergic agonists in patients with
schizophrenia [16–18], and in those with Parkinson’s disease
showing compulsive drug-seeking behaviour [19] or pathological
gambling [20] after chronic DA agonist use. However whilst a
large amount of rodent data support a role for DA sensitization in
the development of drug-self-administration and drug-seeking
behaviour [21–23], decisive PET data in human drug dependency
is relatively lacking [24–26], though enhanced dorsal striatal DA
release in response to drug-related cues has been reported [27,28].
The midbrain dopaminergic nuclei lie at the heart of the brain’s
reward circuitry, projecting to targets that include the striatum,
nucleus accumbens, the orbitofrontal cortex and the amygdala
[29–31]. Contemporary theories suggest that phasic DA release
provides a signal of any discrepancy between received and
anticipated reward (i.e. reward prediction error) which is a vital
‘‘teaching signal’’ for learning [32–34]. Individuals with schizo-
phrenia have been demonstrated to show abnormal associative
learning [35–37] and reward-related BOLD signalling [38–40],
consistent with disruption of these processes being part of the
pathophysiology of this illness [41]. Interestingly, drug addiction is
associated with deficits on tasks linked to orbitofrontal cortical
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function [42–45] and aberrant reward prediction error signals
[46–48]. However, dopamine signalling has also been implicated
in the attribution of motivational significance, or incentive
salience, to environmental cues. In fact, one contemporary theory
of drug addiction suggests an augmentation of this processes, as a
results from mesolimbic sensitization following repeated drug
exposure, explains the powerful motivation for drugs for addicts
[49,50]. This incentive sensitization mechanism has also recently
been used to explain the phenomenology of schizophrenia, with
patients reporting that the world seems imbued with personal
significance [51]. The rewarded gambling task, which includes a
rewarded outcome and anticipation conditions may permit us to
explore the effects of amphetamine sensitization with respect to
both of these models.
Sensitised rodents display similar reward-related deficits [52–
55], aberrant learning [56,57], and abnormal striatal and
orbitofrontal activity [58]. While there is considerable evidence
for the development of AS in primates [59–61], to date no formal
examination of reward processing in humans has taken place.
Preliminary behavioural data suggested that sensitization could be
safely induced in healthy human subjects [62–64]: recent PET
studies have explored the effects of a sensitising dosage regime of
amphetamine on drug-induced dopamine release [65], the
contribution of conditioning to this effect [66] and, more recently,
its interaction with stress [67]. In healthy male volunteers, these
data demonstrated that AS was associated with enhanced drug-
induced dopamine release in the ventral striatum, extending
dorsally into the dorsal caudate and putamen [65].
In this present study we used the same amphetamine dosage
regime as Boileau et al and employed a rewarded gambling
(wheel-of fortune) task [68,69] to explore the impact of sensitiza-
tion on the ability of a low dose of amphetamine to modulate
different aspects of reward processing - namely decision making,
anticipation and outcome processing - in dopaminoceptive brain
regions. We hoped to show, for the first time, that sensitization
would induce altered BOLD signal in key regions of reward-
processing circuitry, specifically the striatum, the orbitofrontal
cortex and the amygdala, during the various phases of our
gambling task, although given the incentive sensitization hypoth-
esis, we propose that reward anticipation is of most interest in this
regard.
Methods
Participants and Design
Our study was designed to explore (1) the feasibility of
demonstrating the translation of a rodent model of dopamine
dysregulation to humans and (2) to characterise the neural
substrates of such mesolimbic sensitization on reward processing
in humans. We were not exploring the effects of repeated
intermittent stimulant exposure on any clinically relevant
measures, nor were we exploring the efficacy of this procedure
using any standard randomised clinical trials design. As such this
work was not deemed a clinical trial by the United Kingdom
MHRA or local ethics committee. However, full ethical approval
for this research project was received from the King’s College
London’s Institute of Psychiatry, Research Ethics Committee
reference# 022/03). Participants were provided with information
sheet at least 24 hours prior to giving consent to take part in the
study. They were given the opportunity to ask questions prior to
giving written informed consent. The wording of both the
participant information sheet and the consent form were approved
by the local ethics committee.
The data reported here is from the same participants as in our
previous paper [70] but salient details will be repeated here in
brief. Twenty-two right handed male volunteers (age 30.8 years
+/28.5 years), were recruited and assigned to receive either four
oral doses of dexamphetamine (20mg), or four doses of a placebo,
following a procedure (albeit with a fixed dose across all
participants) previously shown to produce dopaminergic sensiti-
zation in humans [65]. Subjects received the first 3 doses with a
48-hour inter-dose interval (Sessions 1–3) and again (4th dose)
after a two week wash-out period (Session 4) using a double-blind
procedure. Participants were excluded if they had any past
medical history of note, were taking any medications, or had a
family history of mental illness or substance abuse problems, these
factors were assessed by a clinician and contact with the
participants’ general medical practitioner. However, no standard-
ised psychiatric interview was carried out. Each visit had an initial
drug-urine analysis to exclude the use of recreational drugs. The
subjects in both the placebo and amphetamine groups were
matched in terms of age (p,0.688) and years of education (p,
0.99). Drug use was assessed with a set of five–point scales.
Subjects were asked ‘‘Have you used any of these drugs in the
past?’’ and responded zero for no previous use, one for
experimental use (has tried sporadically), two for occasional use
(uses small quantities from time to time), three for moderate use
(small quantities regularly/large amounts occasionally), and four
for severe use (frequent use of large quantities, often to
intoxication/debilitation). Subjects scoring three or four were
excluded. Neither group differed significantly on these scales for
marijuana (Mean (SD); Placebo 1.25(1.1); Amphetamine
0.636(0.673); p,0.122) or other drug use (Mean(SD); Placebo
0.54(0.52); Amphetamine 0.26(0.47); p,0.212). Participants were
also excluded if they were proficient in playing a musical
instrument or touch typing due to the inclusion of a motor
sequence learning task [71] in the scanning battery. During
screening all subjects were exposed to a mock-scanner to
acclimatise them to the scanner environment, and thereby reduce
session differences related to the novelty of the scanning
environment.
Note that the context in which the drug was administered, and
where participants waited prior to the scan, was carefully
controlled, with the same room employed for all visits. Participants
were scanned approximately 120 minutes post-drug/placebo
administration during sessions 1 (acute exposure) and 4 (following
repeated exposure) in an effort to model the effects of sensitization-
related dopaminergic dysregulation on the neural substrates of
explicit motor sequence learning. During the same scanning
session participants also performed a working memory task, a
motor learning task and a rewarded gambling task: the findings
related to the first two of these tasks are reported elsewhere.
Acquisition of Functional MRI Data
Imaging was performed with a 1.5T GE scanner (GE, USA).
180 volumes (matrix size 64664) with whole brain coverage were
acquired during each functional run. Each volume comprised 36
slices, collected in an interleaved manner, with a slice thickness of
3mm and a 0.3mm gap between slices. The repetition time was 4
seconds, TE= 40ms, flip angle = 90u. Total acquisition time was
18 minutes (1080 seconds). High resolution structural scans were
also acquired (Spoiled Gradient Recalled (SPGR) and High-
Resolution Gradient Echo).
Rewarded Gambling Task
Whilst lying in the scanner subjects performed a block-design
rewarded gambling task (Figure 1). Participants were given a
Amphetamine Sensitisation and Reward Processing
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starting balance of £15 and informed that they would receive any
end balance on completion of the task. On each trial, each
participant was presented with a roulette wheel with 8 sectors.
Three wheel types were employed, with the proportion of red and
black sectors on the wheel manipulated to set the perceived
likelihood of winning at 25%, 50%, and 75%. In fact, the
outcomes were fixed on a trial-by-trial basis to ensure an
approximately equal number of wins and loss trials over the
session. In the decision phase of the task, participants were
presented a cue indicating whether this was a gambling (wager £1)
or control (wager £0) trial and prompting them to make a choice
(red or black when gambling, or yellow and blue during control
trials) within a 2 second decision window: failure to make a choice
led to an automatic loss of £1 on the gambling task. The task
involved alternating 36 second blocks of 5 trials (either rewarded
or control). This reward-control block cycle was repeated 3 times,
giving a total of 15 trials for each probability wheel (25%, 50%,
and 75%). Following the 2 second decision phase, the subjects
waited for a variable delay period of between three and seven
seconds (anticipation) during which the roulette ball rotated
around the outside of the roulette wheel. When the ball came to
rest subjects were informed of the outcome (win or loss) and their
money total was amended accordingly (+£1 for a win, -£1 for a
loss). The total trial length was fixed at 12 seconds (60 second
blocks) and the next trial started immediately after the previous
trial (see Figure 1).
Analysis: Assessment of Psychostimulant Sensitization
On each session measures of both subjective drug effects and
peripheral physiological processes were obtained. The measure-
ment and analysis of these data have been presented in detail
elsewhere [70]. Here, we provide a brief summary of these results
for completeness.
Subjective drug effects were assessed using the Addiction
Research Centre Inventory (ARCI) for amphetamine [72–74],
the Profile of Mood States (POMS) [75], and Visual Analogue
Mood Scales [76] at baseline and every 60 minutes for 240
minutes. Subjects were asked hourly to score each item for ‘‘how
they feel at the present moment’’. Physiological data (eye-blink
rate, pulse and blood pressure, BP) were also collected (seated,
following a resting period of 5 min). Eye-blink rate was taken as
the average number of blinks over a 3 minute period at rest.
We anticipated behavioural (subjective) sensitization to am-
phetamine to mirror previous findings [62–65], including
enhanced amphetamine-like experience, amphetamine-induced
euphoria (ARCI-MBG), profile of mood states activity-vigour,
alertness and attentiveness and positive affect as well as
sensitization of resting eye-blink rate [70]. These hypotheses were
tested using a Group6Administration/Session repeated measures
analysis of variance (rmANOVA) for each dependent variable,
using a level of significance of p,0.05 with Greenhouse-Geisser
correction. All calculations were performed using SPSS15 for
Windows.
Analysis: Reward Gambling Task
A repeated-measures ANOVA (Group-by-Session-by-Trial-type
(i.e. reward or control)-by-probability (of winning)) was used to test
for between-group differences in reaction time. To confirm a
relationship between any significant behavioural and subjective
sensitization observed, we tested for correlations between both
sensitised measures after correcting for individual differences in
inter-session plasma amphetamine concentration (partial correla-
tion). All calculations were performed using SPSS 15 for Windows.
Analysis of Functional MRI Data
After pre-processing, including realignment, image distortion
correction [77,78], and normalisation, statistical analysis was
carried out using the general linear model (GLM) [79,80] as
implemented in Statistical Parametric Mapping 2 (SPM2; Well-
come Trust Centre for Neuroimaging, London, UK). Each
subject’s EPI data were normalised to a MNI EPI template.
Two 1st level (single subject) GLMs were employed. For analysis of
task-related activations in general we constructed a model that
represented gambling and control trials separately but did not
distinguish task phases and used parametric modulation (second
order polynomial expansion of the probability of winning, i.e.
wheel-type). For analysing the main effects of interest, i.e. phase-
and probability-specific activations, we constructed separate
regressors encoding the task phases (Decision, Anticipation, Wins,
and Losses) for each of the 3 wheel-types (i.e. probability of
winning) for both the gambling and control conditions. In all cases,
the vectors encoding the onset and duration of trials were
convolved with a canonical hemodynamic response function [81].
Both models also included six regressors encoding volume to
volume movement as nuisance regressors. The data were high-pass
filtered (cut-off 128s) and corrected for serial correlations using a
first-order autoregressive model.
At the group level, we first employed a repeated measures
Session 6 Task Phase 6 Probability ANOVA model in the
placebo group and explored the main effects of task, and
probability. We then employed three Group 6 Session 6
Probability repeated-measures ANOVAs to test for Group 6
Session interactions, the appropriate test for sensitization-related
effects, and Group 6 Session 6 Probability effects during
rewarded decision-making, reward anticipation, and reward
receipt (wins. losses). Statistical Parametric Maps (SPMs) of the
t-statistic were constructed adjusting the maximum likelihood
estimators for non-sphericity using restricted maximum likelihood.
For both F-tests and t-tests, SPMs were thresholded at p,0.05
following family-wise error (FWE) correction for multiple testing in
anatomically predefined volumes of interest (see below). To assess
the significance of activations outside a priori regions of interest,
we corrected for multiple comparisons (FWE) across the whole
brain.
In regions where we had a priori hypotheses regarding the
effects of repeated amphetamine exposure we corrected for
multiple comparisons across the joint volume of these regions. In
all cases, independently-derived (i.e. anatomically predefined)
ROIs were employed to prevent biased statistical analyses [82].
For the striatum, we employed masks for the subdivisions of the
striatum as defined anatomically by Mawlawi et al., respectively
[83]. We defined the midbrain ROI as a sphere (10mm radius)
around the peak coordinate in the SN/VTA reported by
Wittmann et al. [84]. Additionally, for the orbitofrontal cortex
and amygdala, bilateral anatomical masks were generated using
the Automated Anatomical Labelling atlas [85] as implemented in
Wake Forest University (WFU) PickAtlas. These ROIs, albeit
unilateral, were used to extract regional parameter estimates for
correlation analysis with behavioural measures of sensitization for
the striatal subdivisions, midbrain and amygdalae. Although group
plasma concentration of amphetamine did not differ between
sessions, there was considerable variability in amphetamine
concentration in the blood plasma within-subject and thus partial
correlation analysis, which controlled for session-to-session differ-
ence in amphetamine plasma concentration, was employed.
Amphetamine Sensitisation and Reward Processing
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Figure 1. Experimental Design of the Rewarded Gambling Task. (Top) The task had a blocked design where gambling blocks were
interleaved with control blocks. Each block consisted of 5 trials, each of 12 seconds length. (Middle) Each trial was 12 seconds long and included a 2
second decision period where a wheel (see bottom) was presented which indicated the perceived probability of winning on this trial. During
gambling trials participants were required to make a choice (Red or Black) or they would simply lose the compulsory £1 wager automatically. In the
control condition, subject were still asked to make a choice but were limited to colours other than Red and Black and no money was wagered.
Following the decision, a variable anticipatory delay (4–7 seconds) preceded a 3–6 second outcome phase where the participant was informed of the
outcome of the trial and their balance was amended. Three wheel types were available, each indicating the probability of winning the participant
should expect on that trial.
doi:10.1371/journal.pone.0093955.g001
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Subjective and Behavioural Sensitization to the Effects of
Amphetamine
The analysis of subjective and behavioural sensitization effects is
reported in detail elsewhere [70]. In brief, we found evidence for
sensitization of subjective effects as demonstrated by significant
Group-by-Session interactions for amphetamine-like experience
(p = 0.015), drug-induced euphoria (p,0.009), Activity-Vigour
scale (p = 0.018) and Dreamy-Attentive scale (p = 0.019). In
contrast, physiological measurements (pulse, eye-blinks, and blood
pressure) did not show evidence of sensitization.
Decision-Making Reaction Time
As expected, we found evidence that reaction times were
significantly influenced by trial-type (i.e. rewarded or control;
F(1,20) = 30.72, p,0.001) and probability of winning (F(2,40)
(2,40) = 10.23, p,0.001), with faster reaction times in during
reward trials and trials with a higher-probability of winning.
However, unexpectedly, we also observed a significant main effect
of session (F(1,20) = 49.72, p,0.001) suggestive of a practice effect,
despite the fact that participants were trained on the task prior to
scanning. We found no evidence for a Group6Session (p,0.569)
or Group6 Session6Trial Type (p,0.974) interactions.
Task-Related BOLD Responses
In accord with previous results from similar tasks [68,69] we
found a main effect of task phase in the placebo group in a large
scale fronto-parietal network, including the cingulate and insular
cortices, thalamus and basal ganglia. Furthermore, in the placebo
group we also observed a main effect of probability in the dorso-
medial parietal and occipital lobes (Figure 2 and Table S1).
Finally, while we found no phase-by-probability interactions which
were significant following whole-brain correction for multiple
comparisons. However, using an a priori ROI we found evidence of
a significant task-phase by probability interaction in the right
limbic striatum which survived small volume correction (Z-score
3.25; p = 0.038; [21 15 23]).
Decision-making
We found evidence for a significant Group 6 Session
interaction in decision-making related BOLD responses in the left
([26 12 12], Z-score = 3.13, p-corrected=0.038) and right caudate
nucleus ([12 0 21], Z-score = 3.04, p-corrected=0.05). As is clearly
shown in figure 3, this interaction is driven by a significant
reduction in decision-making related BOLD signal following
sensitization. However, we found no evidence for a significant
Group 6 Session 6 Probability interaction during decision-
making.
Anticipation
As during the decision phase, we also found evidence for a
significant Group 6 Session interaction in anticipation-related
BOLD response in the left ([215 24 6], Z-score = 3.15, p-
corrected=0.043) and right caudate nucleus ([9 12 9], Z-
score = 3.14, p-corrected=0.038). However, unlike the effect during
decision making, and shown in figure 4, this interaction is driven
by a significant increase in anticipation-related BOLD signal in the
amphetamine group. To demonstrate that this effect was related to
sensitization, we used a partial-correlation analysis (controlling for
individual between-session differences in plasma amphetamine
concentration) to test for a significant relationship between the
change in anticipation-related BOLD signal in the caudate nucleus
and sensitization of subjective measures of amphetamine-like
experience. This analysis found that sensitization to amphet-
amine’s subjective effects (ARCI: Amphetamine) was positively
correlated with the change in BOLD response during reward
anticipation – over and above anticipation of a non-rewarded
outcome – in the right caudate nucleus (r = 0.623, p(1-
tailed) = 0.027). Again, we found no evidence for a significant
Group6 Session6Probability interaction.
Outcome Processing (Wins.Loss in Rewarded Trials)
We found evidence for a Group 6 Session interaction in
outcome-related BOLD response in the amygdalae bilaterally.
However, this interaction was driven by a significant reduction in
amygdala BOLD signal change in response to wins compared to
losses following repeated amphetamine-exposure effect in the right
amygdala ([33 23 227], Z-score = 3.53, p-corrected=0.006), (see
Figure 5). Again, partial-correlation analysis (controlling for
individual between-session differences in plasma amphetamine
concentration) was used to test for a significant relationship
between the change in outcome-related BOLD signal in the
amygdala and sensitization of subjective measures of amphet-
amine-like experience. This analysis found that sensitization to
amphetamine’s subjective effects (ARCI: Amphetamine) was
positively correlated with the change in BOLD response to
rewarded outcomes compared to losses (r = 0.636, p=0.048).
Discussion
This study found enhanced subjective responsiveness to
amphetamine consistent with earlier work on dopaminergic
sensitization in humans [62–65], though in contrast, physiological
sensitization effects (changes in blink rate or blood pressure) were
not observed and there were no differential effects on any aspects
of reaction time compared to those receiving placebos. The fMRI
results suggests a significant sensitization effect in the caudate
nucleus and amygdala. Following repeated amphetamine expo-
sure, the caudate nucleus showed reduced BOLD signal during
decision-making, but enhanced BOLD activity during reward
anticipation, which was correlated with the degree of sensitization.
The amygdala BOLD response to reward outcomes was reduced
following repeated amphetamine exposure, and this change was
correlated with the degree of sensitization sensitization.
Surprisingly, despite our previous finding of a significantly faster
reaction time following sensitization during a working memory
[70], we did not find any sensitization of response time here. This
is puzzling, but it may reflect a floor effect with little additional
improvement compared to performance following the first
amphetamine administration. Alternatively, the significant session
effect observed may have masked the effect. This session effect is
unexpected because participants were pre-trained on the task in an
attempt to minimise these effects. This is a potentially important
confound of our analysis of the BOLD response during decision-
making, although the modelling of these events as a fixed 2-second
window may ameliorate some of its impact. Nonetheless, the
results of the decision-making phase of this task must be
considered with this potential confound in mind.
The observed changes in the ‘‘associative striatum’’ (caudate
nucleus) are in accord with previous PET studies of sensitization in
healthy humans [65], cue-induced DA release in addiction [28]
and drug-induced DA release in schizophrenia [17,18]. Sensitiza-
tion is also associated with an accelerated development of
behaviours which are mediated by dorsal striatal DA transmission,
namely stereotypy [86], outcome-insensitive behaviour [52] and
stimulus-response ‘‘habit’’ formation [87–89]. While these findings
are consistent with enhanced DA release in the dorsal striatum –
posited linked to increased driving of ascending striato-nigrostri-
Amphetamine Sensitisation and Reward Processing
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atal loop circuitry [90,91] by sensitised mesolimbic stimulation of
accumbens D1 receptors – the opposing direction of the effects is
surprising. DA release blunts spontaneous neuronal activity in the
neostriatum and accumbens and increases the efficacy of
glutamatergic signalling at dendritic spines [92]. It is likely that
this reflects an interaction between differential task-related cortico-
striatal inputs (e.g. hippocampus or prefrontal cortex), task-evoked
DA release and elevated basal dopamine concentrations following
sensitization, indeed, these factors likely explain the lack of a
sensitization-related change in the BOLD contrast (rewarded vs
non-rewarded) conditions in the ventral (limbic) striatum. Specif-
ically regarding the associative striatum, the reduced response
observed during decision-making may reflect the blunting of the
normal response in this region due to elevated synaptic dopamine
[93]. Importantly, changes in the placebo group also contributed
to this interaction, and likely reflect a change in the confidence
regarding the reward delivery, given the change in reaction time
discussed above. Furthermore, in the amphetamine group this
effect was not significantly related to the degree of sensitization
seen when individual differences were examined, and therefore
may reflect a more general impact of repeated amphetamine
exposure. Together, these findings, including a potential behav-
ioural confound (i.e. a change in reaction time) suggest we should
show some caution regarding the observed interaction during
rewarded decision making.
We also observed a significant interaction in the associative
(ventro-medial) caudate nucleus during reward anticipation.
Importantly, as there are no motor responses during this condition
and thus the changes observed are not confounded by changes in
reaction time. Nonetheless, the interaction was driven both by a
Figure 2. Upper Panel: Brain regions identified as displaying sensitivity to the task phases (i.e. decision, anticipation, wins and
losses) in the placebo group (left panel). Parameter estimates for key dopaminergic and reward-related areas showing a significant main effect
of task (right panel). Lower Panel: Brain regions where BOLD signal was modulated by reward probability the placebo group (left panel). Parameter
estimates from the occipital cortex and precuneus, regions that display a significant main effect of reward probability. All parameter estimates reflect
the mean response in arbitrary BOLD units. Results are shown with the standard error of the mean.
doi:10.1371/journal.pone.0093955.g002
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reduced responsiveness is the placebo group and increased
anticipation-related activity, during rewarded trials compared to
those when no reward was available. Importantly, elevated
anticipation-related activity was significantly correlated with the
degree of sensitization. We propose that this effect is driven by
elevated excitability of striato-nigrostriatal loops [94] due to
excessive nucleus accumbens dopamine release, with a resultant
aberrant recruitment of the dorsal caudate during reward
anticipation. This mechanism may be linked to the faster
development of response habits following sensitization in rodents
[89], a mechanism also implicated in addiction [95] and is linked
to ‘‘dopamine-dependent serial connectivity between the ventral
and dorsal striatum’’ [96]. These theories are also consistent with
the incentive sensitization model [97], and our findings likely
support the idea that sensitization alters the motivational
significance of environmental events and cues in humans.
Amygdala dysfunction is argued to be a core pathophysiological
mechanism in the development of addiction [98,99] and has been
demonstrated to be disrupted in schizophrenia [100]. Whilst
commonly associated with the processing of fearful stimuli, there is
a considerable body of evidence suggesting that the amygdala is
also recruited during reward learning and Pavlovian behavioural
responses [101,102] and is seen in neuroimaging studies of reward
outcome sensitivity – that is gains over losses [103]. The amygdala
is heavily targeted by mesolimbic DA neurons which strongly
modulate its activity [104]. It has been implicated in reward-
seeking behaviour [105] and can drive cue-dependent drug-
seeking behaviour [106,107]. Concerning sensitization, the ability
of the basolateral amygdala to modulate medial prefrontal neurons
is augmented following a single acute amphetamine exposure but
blunted by repeated amphetamine exposure, a process which
depends on mesolimbic DA signalling [108]. Overall, it is possible
that the reduced sensitivity to differential outcomes (i.e. gains.
loss) may reflect a sustained elevation of amygdala activity
associated with kindling, a process related to sensitization or
perhaps more likely, the effects of an elevation in mesolimbic
Figure 3. Significant Group6Session interaction in the caudate nucleus during the decision-making phase of our gambling task
(p,0.05, corrected). The right panel shows parameter estimates (in the order placebo at scan 1, placebo at scan 2, AS at scan 1 (before
sensitisation), AS at scan 2 (after sensitisation)) from the mean from an associative striatal ROI. Note that this plot is merely used to illustrate the
nature of the interaction effect. All parameter estimates reflect the mean response in arbitrary BOLD units. Results are shown with the standard error
of the mean.
doi:10.1371/journal.pone.0093955.g003
Figure 4. Significant Group 6 Session interaction (p,0.05, corrected) during the anticipation phase of our gambling task (left
panel). To illustrate the nature of the interaction effect, the middle panel shows parameter estimates (in the order placebo at scan 1, placebo at scan
2, AS at scan 1 (before sensitisation), AS at scan 2 (after sensitisation) from the mean response within an associative striatal ROI. The graph on the
right shows the correlation between sensitisation-related change in striatal BOLD signal during anticipation and the change in subjective response to
amphetamine. All parameter estimates reflect the mean response in arbitrary BOLD units. Results are shown with the standard error of the mean.
doi:10.1371/journal.pone.0093955.g004
Amphetamine Sensitisation and Reward Processing
PLOS ONE | www.plosone.org 7 April 2014 | Volume 9 | Issue 4 | e93955
dopamine in this region. The apparently paradoxical positive
correlation between sensitization to the drug’s subjective effects
and the change in the response (i.e. reduction) of the amygdala,
but given that fMRI is non quantitative and dependent upon
BOLD contrast, this result could reflect a change either in reward
sensitivity (i.e. to wins) or perhaps more likely, an increased
responsiveness of the amygdala to losses. These findings speak
potentially to two separate neuroplastic mechanisms at play.
Specifically, at a group level the amygdala may display an
enhanced sensitivity to losses, perhaps consistent proposals of
allostatic changes in opponent processes following drug withdraw-
al-related to negative emotional states [109], which it is proposed
my drive reinstatement of drug use. However, those individuals
who have a greater propensity to develop sensitization, are to some
degree protected from this effect. Importantly, these subjects are
necessarily dysphoric at the time of scanning, in fact the visual
analogue scales would suggest otherwise, but they had consumed
amphetamine shortly before the scan. Additionally, while the
neuroplastic (potentially allostatic) effects may endure, the
subjective effects of withdrawal may not last long after so few
exposures to such a low dose. This finding may be of particular
importance given the amygdala’s role in updating value represen-
tations and attribution of incentive salience to environmental cues,
such as the reward wheel, which remained on screen during
outcome delivery.
Contrary to our expectations, sensitization was not associated
with changes in either the nucleus accumbens or in the
orbitofrontal cortex (OFC) during reward outcome processing.
In the nucleus accumbens, this might be explained by saturation of
post-synaptic D1 receptors (a ceiling effect), given the strong
relationship between D1 stimulation and accumbens BOLD signal
[110]. Concerning the lack of sensitization effects in the OFC, our
acquisition deliberately employed a long repetition time to permit
us to collect a large number of thin slices to minimise the
susceptibility ‘‘drop-out’’ effects [111]. This was chosen because
the OFC is vulnerable to drop out effects in fMRI and changes in
the orbitofrontal cortex were predicted. The lack of OFC
sensitization effects is all the more puzzling given the observed
changes in the amygdala, a brain region with strong reciprocal
connectivity with the OFC [112,113]. An examination of the
imaging masks confirmed that the absence of an effect was not
related to a lack of coverage which accords with observed task-
related recruitment of this region. It could be argued that this
absence simply reflects the fact that our participants have only
received 4 doses of amphetamine, a far shorter dosing regimen
than those used in rodent and primates studies. However, there is
some evidence that hyper-excitability of orbitofrontal neurons is
one of the earliest observed neuroadaptations in rodents [58]. As
described elsewhere [70], 10/11 subjects in each group were
homozygous for the Val158Met polymorphism. However, these
same subjects were also genotyped for a novel polymorphism of
the DAT gene which has been linked to the propensity to abuse
cocaine [114]. We found a relatively even split of the risk allele in
these subjects, and in a brief report published elsewhere [115], we
found that this polymorphism significantly modulated the effects of
acute amphetamine on reward-related recruitment of orbitofrontal
cortex. The effect of this polymorphism on the development of
sensitization remains to be determined, but it may explain our
failure to detect a significant sensitization-related change in the
OFC.
There are a number of limitations with this study that should be
highlighted. Firstly, the sample size is relatively small. Nonetheless,
we have previously demonstrated an effect of sensitization during
working memory [70] and motor sequence learning [71].
Furthermore, the evidence that sensitization of mesolimbic
dopamine release is evident up to one year after first expression
[65] was published during our data collection and raised concerns
about collecting a larger sample. Secondly, the repetition time for
the scan was quite long, which perhaps reduced our sensitivity to
detect some effects. The fact that we used a fixed dose of 20mg for
all participants, rather than a weight titrated dose was agreed with
our ethics committee and local pharmacy on the basis of a typical
dose used clinically. Clearly, titrated doses would have been
preferable, and may explain some of the heterogeneity in the
observed effects. Note however, that there was no evidence for a
significant difference in drug plasma levels during the scanning on
the first and last visit and therefore, while some variability on the
expression of sensitization was anticipated, it is possible that some
component of this could be explained by this fixed dose. While we
screened all participants for recent drug use on every visit, our
information on previous drug history was based solely on
subjective report. However, the level of previous drug use was
extremely low, particularly in our amphetamine group. While,
some very infrequent recreational use was reported by some
participants, none reported prolonged administration of thera-
peutic stimulants for either weight-loss or treatment of ADHD,
Figure 5. Significant Group 6 Session interaction (p,0.05, corrected) in the right amygdala during the outcome phase (i.e.
Wins.Loss) of our gambling task (left panel). To illustrate the nature of the interaction effect, the middle panel shows parameter estimates (in
the order placebo at scan 1, placebo at scan 2, AS at scan 1 (before sensitisation)), AS at scan 2 (after sensitisation) from peak voxel within the right
amygdala. Additionally, the graph on the right shows the correlation between sensitisation-related change in amygdala BOLD signal during outcome-
processing and the change in subjective report of amphetamine-like experience. All parameter estimates reflect the mean response in arbitrary BOLD
units. Results are shown with the standard error of the mean.
doi:10.1371/journal.pone.0093955.g005
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which would have been an exclusion criterion. Furthermore,
participants’ doctors were contacted before they were finally
recruited to ensure that pre-existing conditions that would bar
entry to the study were not concealed. As our study was focused on
sensitization as a model of dopamine dysregulation in schizophre-
nia, rather than addiction, we did not collect an index of drug
liking vs drug wanting. This was an unfortunate oversight, as given
the incentive sensitization model which has be suggested, in the
aberrant salience hypothesis [51] to be important in schizophre-
nia. In an ideal world, the participant could have been dosed and
waited in the scanning environment prior to the scanning
beginning. Unfortunately, this was not possible, but the context
was carefully controlled with all participants staying in the same
room for all 4 sessions, with dosing and scanning at the same fixed
times of the day. We feel that this minimised the potential impact
of any contextual confounders. Finally, while all participants were
of normal healthy weight when recruited, and none reported any
change in their eating habits, it is possible that some of the
observed effects could be driven by changes in body weight
because we did not weigh participants on every visit.
We found evidence for blunted responses in the caudate and
amygdala, suggestive of altered processing within salience and
motivational circuits during decision-making and reward process-
ing in the amphetamine group, although these effects were likely
reflecting more general effects of repeated amphetamine exposure.
However, the enhanced dorsal striatal responses during reward
anticipation are suggestive of findings in rodents and may speak to
increased motivational drive for reward, and processes which
would ultimately result in reduced sensitivity to reward outcomes,
such as is seen in drug addiction and patients with schizophrenia.
Overall, this data speaks to disruption of neural systems and
processes linked to RPE-dependent learning mechanisms, but
perhaps not in a sensitization specific manner. Whereas, sensiti-
zation-related effects were evident related to the anticipation of a
rewarded, compared to a non-rewarded, outcome. Amphetamine
sensitization in otherwise healthy volunteers implicates many of
the same structures and processes observed previously in rodents,
an suggests that this translational and translatable model yields
insights to potentially important mechanisms underlying the
development of both addiction and schizophrenia, and may
explain their relatively high comorbidity [12,116].
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